Quotables
"We are probably nearing the limit of all we can know about astronomy."
Simon Newcomb, astronomer ; 1888
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8124103 | Influenza antigens, vaccine compositions, and related methods The present invention relates to the intersection of the fields of immunology and protein engineering, and particularly to antigens and vaccines useful in prevention of infection by influenza virus. Provided are recombinant protein antigens, compositions, and method... | 02/28/2012 |
| 8080255 | Functional influenza virus like particles (VLPs) The present invention discloses and claims virus like particles (VLPs) that express and/or contains seasonal influenza virus proteins, avian influenza virus proteins and/or influenza virus proteins from viruses with pandemic potential. The invention includes vector ... | 12/20/2011 |
| 7993655 | Vaccine for avian influenza and methods of use The subject invention pertains to influenza vaccines and particularly avian influenza vaccines (AIV). The invention includes methods for preparing transgenic plant cells to express know HA1 polypeptides having specified homologies that are used to prepare vaccine co... | 08/09/2011 |
| 7384642 | Canine influenza vaccines The present invention encompasses influenza vaccines, in particular canine influenza vaccines. The vaccine may be a recombinant poxvirus vaccine or an inactivated vaccine. The invention also encompasses recombinant poxvirus vectors encoding and expressing influenza ... | 06/10/2008 |
| 7316813 | Influenza vaccine composition An inactivated influenza virus preparation is described which comprises a haemagglutinin antigen stabilized in the absence of thiomersal, or at low levels of thiomersal, wherein the haemagglutinin is detectable by a SRD assay. The influenza virus preparation may com... | 01/08/2008 |
| 7271312 | Modified nucleic acid sequences and methods for increasing mRNA levels and protein expression in cell systems The invention provides modified recombinant nucleic acid sequences (preferably DNA) and methods for increasing the mRNA levels and protein expression of proteins which are known to be, or are likely to be, difficult to express in cell culture systems, mammalian cell... | 09/18/2007 |
| 7270990 | Virus production An improved process for recovery of virus from allantoic fluid of virus-infected chick embryos. Virus associated with granular and fibrous debris in the allantoic fluid can be disassociated from the debris and recovered, thereby increasing viral yield. Dissociation ... | 09/18/2007 |
| 7244435 | DNA vaccine expressing HA1 of equine-2 influenza virus The invention is for a DNA vaccine expressing the hemagglutinin (HA1) gene of equine-2 influenza virus. By engineering a stop codon within HA1, expression of HA1 is ensured. By encapsulation of the DNA vaccine in liposome and by intranasal inoculation, it is suffici... | 07/17/2007 |
| 7226775 | Method of removing endotoxin from vaccines A method of removing bacterial endotoxin from a pharmaceutical process solution is disclosed. In one embodiment, the method comprises treating the solution with a surfactant effective to dissociate the endotoxin from a pharmaceutical drug or vaccine substance in the... | 06/05/2007 |
| 7208293 | Directed evolution of novel binding proteins In order to obtain a novel binding protein against a chosen target, DNA molecules, each encoding a protein comprising one of a family of similar potential binding domains and a structural signal calling for the display of the protein on the outer surface of a chosen... | 04/24/2007 |
| 7189800 | Replikin peptides in rapid replication of glioma cells and in influenza epidemics Peptides of influenza virus hemagglutinin protein and Plasmodium falciparum malaria antigen, antibodies specific for the peptides, influenza vaccines, malaria vaccines and methods of stimulating the immune response of a subject to produce antibodies to influe... | 03/13/2007 |
| 7172892 | Nucleic acid molecules encoding serine protease CVSP14, the encoded polypeptides and methods based thereon Provided herein are polypeptides designated CVSP14 polypeptides that exhibit protease activity as a single chain or as an activated two chain form. Methods using the polypeptides to identify compounds that modulate the protease activity thereof are provided. The pol... | 02/06/2007 |
| 7169395 | Multivalent immunogenic composition containing RSV subunit composition and influenza virus preparation Immunogenic compositions for administration to adults, particularly to the elderly, to protect them against disease caused by infection by respiratory syncytial virus and by influenza virus comprise an immunoeffective amount of a mixture of purified fusion (F) prote... | 01/30/2007 |
| 7135188 | Methods and compositions for immunotherapy of cancer Methods and vaccines for suppressing formation of or inhibiting growth of tumors in a host are provided, via administration of a vaccine containing either a fusion protein of the tumor associated antigen fused to a truncated form of listeriolysin or a recombinant fo... | 11/14/2006 |
| 7125703 | Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon Provided herein are type II transmembrane serine protease 7 (MTSP7) polypeptides. Zymogen and activated forms of these polypeptides as well as single and two chain forms of the protease domain are also provided. Methods using the polypeptides to identify compounds t... | 10/24/2006 |
| 7112430 | Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon Provided herein are type II transmembrane serine protease 10 (MTSP10) polypeptides. Zymogen and activated forms of these polypeptides as well as single and two chain forms of the protease domain are also provided. Methods using the polypeptides to identify compounds... | 09/26/2006 |
| 7105333 | Nucleic acid molecules encoding a transmembrane serine protease 9, the encoded polypeptides and methods based thereon Provided herein are type II transmembrane serine protease 9 (MTSP9) polypeptides. Zymogen and activated forms of these polypeptides as well as single and two chain forms of the protease domain are also provided. Methods using the polypeptides to identify compounds t... | 09/12/2006 |
| 7049121 | Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use The invention provides twenty-one butyrylcholinesterase variants having increased cocaine hydrolysis activity as well as the corresponding encoding nucleic acids. The invention further provides methods of hydrolyzing a cocaine-based butyrylcholinesterase substrate a... | 05/23/2006 |
| 6951649 | Methods of making neuraminidase-supplemented compositions The present invention relates to a method for formulating a vaccine composition which comprises an anti-influenza vaccine, wherein the improvement of the vaccine composition is that the vaccine includes, as an additive, neuraminidase (NA). The base anti-influenza va... | 10/04/2005 |
| 6866853 | Interferon inducing genetically engineered attenuated viruses The present invention relates to genetically engineered attenuated viruses and methods for their production. In particular, the present invention relates to engineering live attenuated viruses which contain a modified NS gene segment. Recombinant DNA techniques can ... | 03/15/2005 |
| 6855321 | Polyepitope carrier protein The invention relates to polyepitope carrier proteins that comprise at least five CD4+ T cell epitopes, for conjugation to capsular polysaccharides. The carrier proteins are use useful as components of vaccines that can elicit a T-cell dependent immune response. The... | 02/15/2005 |
| 6814981 | Ganglioside immunostimulating complexes and uses thereof An immunostimulating complex comprising one or more ganglosides, illustrated by the ganglosides GM2, GD2, GD3 or GT3, is useful as a prophylactic or therapeutic agent in the treatment of tumors, inter alia, especially melanomas. ... | 11/09/2004 |
| 6780421 | Adjuvant for a vaccine composition An amphipathic compound including a sterol-derived lipophilic grouping bound to a cationic grouping for use as an adjuvant in the delivery of a vaccine composition. In a particular embodiment, the lipophilic grouping is a cholesterol derivative and the cationic grou... | 08/24/2004 |
| 6572861 | Adjuvants for use in vaccines The invention relates to adjuvants that contain a lecithin, an oil and an amphiphilic surfactant and that are capable of forming a stable oil-in-water emulsion vaccine so as to minimize local reactions to the vaccine in the injected animal.... | 06/03/2003 |
| 6565852 | Methods and compositions for immunotherapy of cancer Methods and vaccines for inducing an immune response to a tumor associated antigen in a host are provided wherein the vaccine contains either a fusion protein of the tumor associated antigen fused to a truncated form of listeriolysin or a recombinant form... | 05/20/2003 |
| 6485729 | Neuraminidase-supplemented compositions An anti-influenza vaccine composition wherein the improvement is that the vaccine includes, as an additive, neuraminidase (NA). The base anti-influenza vaccine can be any commercially available anti-influenza vaccine. The composition can include and be ad... | 11/26/2002 |
| 6403363 | Method of preservation of vaccines with polybiguanide A method for preventing or reducing bacterial contamination of a viral vaccine is disclosed. The method comprises adding an effective preserving amount of a polybiguanide-containing preservative composition to a solution containing vaccine virus or virus ... | 06/11/2002 |
| 6387373 | Vaccines containing paucilsmellar lipid vesicles as immunological adjuvants The present invention features an adjuvanted vaccine, and methods for preparing an adjuvanted vaccine, preferably for immunizing against influenza, where the adjuvant is a lipid vesicle, and preferably is a nonphospholipid, paucilamellar lipid vesicle. Th... | 05/14/2002 |
| 6372223 | Influenza virus vaccine composition This invention describes an influenza virus vaccine containing an influenza virus antigen obtained from a cell culture, with an influenza virus antigen content between 1 μg and 5 μg per dose and aluminum as an adjuvant as well as a method for its prepar... | 04/16/2002 |
| 6183772 | Doped colorimetric assay liposomes The present invention provides compositions comprising colorimetric assay liposomes. The present invention also provides methods for producing colorimetric liposomes and calorimetric liposome assay systems. In preferred embodiments, these calorimetric lip... | 02/06/2001 |
| 6048536 | Vaccine compositions The invention relates to a vaccine composition adapted for mucosal administration, and in particular for intranasal administration, the composition comprising an influenza virus antigen or antigens, such as haemagglutinin and neuraminidase influenza virus... | 04/11/2000 |
| 6048537 | Method for preparing an influenza virus, antigens obtained and applications thereof Method for preparing purified influenza antigens from a fluid containing influenza virus, comprising the steps of concentration, purification, fragmentation and, where appropriate, inactivation, characterized in that: A. either the purification step entails se... | 04/11/2000 |
| 5976552 | Virus vaccines Improved mammalian virus vaccines are combinations that contain an immunogenic amount of inactivated virus, such as influenza virus, Herpes varicella virus, measles virus, Epstein Barr virus, respiratory syncytial virus, parainfluenza 3, Herpes simplex ty... | 11/02/1999 |
| 5948410 | Influenza vaccine The present invention is concerned with an Influenza surface antigen vaccine obtainable by production from Influenza Viruses propagated on animal cell culture and having a host cell DNA content equal to or less than 25 pg per dose. The present invention i... | 09/07/1999 |
| 5916879 | DNA transcription unit vaccines that protect against avian influenza viruses and methods of use thereof The present invention describes a reliably protective avian vaccine that contains a DNA transcription unit comprising a nucleic acid that encodes a viral protein. This effective and reliable avian vaccine significantly improves upon that which heretofore ... | 06/29/1999 |
| 5858368 | Vaccine comprising a baculovirus produced influenza hemagglutinin protein fused to a second protein A method of preparing a recombinant influenza vaccine using DNA technology is provided. The resulting vaccine is a multivalent, preferably trivalent, influenza vaccine based on a mixture of recombinant hemagglutinin antigens cloned from influenza viruses ... | 01/12/1999 |
| 5830702 | Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response Vaccines comprising an attenuated strain of Listeria spp. expressing a selected foreign antigen and methods of eliciting protective immunity by administering an effective amount of the vaccine are provided. The vaccines of the present invention are design... | 11/03/1998 |
| 5762939 | Method for producing influenza hemagglutinin multivalent vaccines using baculovirus A method of preparing a recombinant influenza vaccine using DNA technology is provided. The resulting vaccine is a trivalent influenza vaccine based on a mixture of recombinant hemagglutinin antigens cloned from influenza viruses having epidemic potential... | 06/09/1998 |
| 5744141 | Flavivirus recombinant poxvirus immunological composition What is described is a recombinant poxvirus, such as vaccinia virus, fowlpox virus and canarypox virus, containing foreign DNA from flavivirus, such as Japanese encephalitis virus, yellow fever virus and Dengue virus. In a preferred embodiment, the recomb... | 04/28/1998 |
| 5741493 | Vaccine composition against influenza, with synergic effects, containing influenza virus core as an additive The use, when preparing a vaccine composition containing a standard influenza virus vaccine, of an additive which consists of a core or core fraction of at least one influenza virus, especially a fraction containing protein M; and a vaccine composition th... | 04/21/1998 |
